No Picture
Trading Ideas

Rural Families Struggle With Work and School With No Home Internet

As many schools around the country start the year virtually, residents in rural communities like those in West Virginia are asking why they don’t have reliable Internet service. The recent bankruptcy of Frontier Communications provides insight into how U.S. broadband policies have fallen short for many Americans. Photo Illustration: Carlos Waters/ Video: Jake Nicol/​WSJ …read more […]

No Picture
Trading Ideas

Oil Climbs Above $43 in New York as Goldman Strikes Bullish Tone

(Bloomberg) — Oil rose above $43 a barrel in New York to its highest closing level since early March amid a broader rally in equities and as China’s economic recovery continued.West Texas Intermediate futures snapped a two-day drop, rising 1.4% as of 2:34 p.m. in Dubai, while Brent crude for November settlement climbed around the same amount to $46.47.Data showed that China rebounded further in August as the world’s second-largest economy emerges from its coronavirus-induced slump. That helped push up global stocks for a second day, while U.S. Treasuries fell as investors moved out of havens.Goldman Sachs Group Inc. in …read more […]

No Picture
Trading Ideas

What’s Next for Wirecard?

Aug.31 — Nigel Verdon, chief executive officer at Railsbank Technology, discusses the assets the company is purchasing from Wirecard U.K. and the advantage of the technology they’ve acquired. He speaks on “Bloomberg Markets: European Open.” …read more […]

No Picture
Trading Ideas

Hybrid, Electric Car Sales Soar in Europe

Aug.31 — Hybrid and electric car registrations soared in Europe last month. They grabbed a record share of the autos market overall and have lifted sales to the highest in 10 months. Plug-in hybrid sales have more than quadrupled while battery electric vehicles more than doubled according to auto market researcher Jato Dynamics. Bloomberg’s Tara Patel reports on “Bloomberg Markets: European Open.” …read more […]

No Picture
Trading Ideas

Wirecard Inquiry Probes Why Germany Missed Fraud of Century

(Bloomberg) — Germany’s blame game over Wirecard AG’s collapse is focusing in on the question of why authorities failed to take a harder look at the payments company before it became the country’s biggest accounting scandal in living memory.Lawmakers will question a top adviser to Chancellor Angela Merkel on Monday in Berlin before grilling financial industry watchdogs the following day as the fraud that burned investors engulfs the country’s political establishment. If the hearings go badly, parliament may start a deeper investigation as the country prepares for the post-Merkel era in an election next year.Wirecard’s crash from rising star to …read more […]

No Picture
Trading Ideas

Nestle to Buy Allergy Treatment Maker in $2.6 Billion Deal

(Bloomberg) — Nestle SA agreed to buy Aimmune Therapeutics Inc. in a $2.6 billion deal, adding a leader in the treatment of peanut allergies in its biggest health-science push yet.The Swiss owner of Nespresso will pay $34.50 a share for the U.S. biotech firm, almost triple its market value. Aimmune makes Palforzia, the first regulatory-approved treatment to help reduce allergic reactions to peanuts in children and teens in the U.S.Chief Executive Officer Mark Schneider has been cultivating Nestle’s health-science arm while shedding slower-growing businesses in areas such as bottled water and sweets. Palforzia, which exposes patients to small doses of …read more […]

No Picture
Trading Ideas

The Race for Japan’s New Prime Minister

Aug.31 — Japan’s ruling party is set to decide the process for picking a new prime minister tomorrow after long-serving leader Shinzo Abe resigned for health reasons on Friday. Local reports put Abe’s right-hand man as the favorite for the top job. Bloomberg’s Stephen Engle reports on “Bloomberg Daybreak: Europe.” …read more […]

No Picture
Trading Ideas

Nestle to buy Aimmune, valuing allergy treatment maker at $2.6 billion

Nestle said on Thursday it was offering $34.50 per share for the remaining 74.4% in peanut allergy treatment maker Aimmune Therapeutics it does not already own as it adds what it hopes will be a lucrative treatment to its portfolio. The offer values the California-based biopharmaceutical company at $2.6 billion, including the $473 million that Nestle had already invested in Aimmune, Nestle said in a statement. The price represents a 174% premium to Aimmune’s closing share price on August 28 of $12.60, said the food giant, which has been gearing its traditional portfolio towards health and wellness products. …read more […]